Regavirumab Overview

Introduction of Regavirumab

Regavirumab, also named TI-23 or MCA-C23, is a monoclonal antibody specifically designed to bind to glycoprotein B (gB) of Human Cytomegalovirus (HCMV). Initially developed by Teijin Pharma Ltd, regavirumab received orphan drug status for HCMV infection from the Pharmaceuticals and Medical Devices Agency (PMDA). HCMV is a widespread pathogen that poses significant risks to immunocompromised individuals such as organ transplant recipients, pregnant women, and those with HIV/AIDS. HCMV can cause severe complications such as pneumonitis, hepatitis, gastrointestinal disorders, and retinitis. Once inside the host, HCMV establishes latency primarily in myeloid lineage cells. During reactivation, the virus resumes replication and spreads to various organs, utilizing gB to infect a wide range of cell types. The virus's persistent replication and immune evasion strategies exacerbate disease pathogenesis.

The Mechanism of Regavirumab Action

HCMV infection can result in a broad spectrum of diseases like CMV retinitis, CMV pneumonitis, and congenital CMV infection, particularly in immunocompromised patients. Regavirumab is designed to specifically target glycoprotein B (gB) of HCMV and is essential for treating HCMV infection. Glycoprotein B is a highly conserved protein across the herpesvirus family and is a vital component of the HCMV envelope. It facilitates viral entry into host cells through either direct fusion or endocytosis-dependent pathways. Structurally, gB includes a signal peptide, an ectodomain responsible for receptor binding, a transmembrane domain, and a cytoplasmic tail that mediates intracellular signaling and trafficking. gB is present on the viral envelope and is essential for the initial contact between HCMV and the host cell. The viral entry process begins with gB binding to cellular receptors, triggering a series of conformational changes that lead to membrane fusion and viral entry. HCMV can remain latent within the host and reactivate under favorable conditions, leading to chronic infection and increased morbidity. The specific binding of gB to its receptors is necessary for viral replication and spread, making the disruption of this interaction a promising therapeutic strategy for HCMV infection. Regavirumab exerts its therapeutic effects primarily through high-affinity binding to a specific epitope on gB. By binding to this epitope, regavirumab inhibits the interaction with host cell receptors and neutralizes the virus. This blockade prevents the conformational changes required for membrane fusion, which is essential for viral entry into host cells.

What We Provide

Regavirumab

Anti-Human Cytomegalovirus Glycoprotein B Recombinant Antibody (Regavirumab)

High-quality regavirumab is provided on Creative Biolabs. The product is designed for use in FuncS, IF, Neut, ELISA, FC, IP, ICC and most other immunological methods, and it is intended for lab research use only, not for diagnostic, therapeutic, or any in vivo human applications.

SpecificationTested Data

• Immunogen
• The details of the immunogen for this antibody are not available.

• Host Species
• Human

• Derivation
• Human

• Type
• IgG1 - kappa

• Species Reactivity
• HHV-5

• Applications
• Suitable for use in FuncS, IF, Neut, ELISA, FC, IP, ICC and most other immunological methods.

• CAS
• 153101-26-9

• Generic Name
• Regavirumab

• Related Disease
• Cytomegalovirus (CMV) infections

View more details

SDS-PAGE

Figure 1 Anti-Human Cytomegalovirus Glycoprotein B Recombinant Antibody (Regavirumab) (TAB-894) in SDS-PAGE

SDS-PAGE analysis of TAB-894 in non-reduced (Lane 1) and reduced (Lane 2) conditions.

HPLC

Figure 2 Anti-Human Cytomegalovirus Glycoprotein B Recombinant Antibody (Regavirumab) (TAB-894) in HPLC

HPLC analysis of TAB-894 shows the purity is>95%.

For research use only. Not intended for any clinical use.